D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reissued by D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $36.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on OMER. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Tuesday, April 1st. StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Omeros presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Down 11.3%

Shares of NASDAQ:OMER opened at $3.93 on Tuesday. The company’s fifty day moving average is $7.21 and its two-hundred day moving average is $8.12. Omeros has a 12-month low of $3.00 and a 12-month high of $13.60. The company has a market cap of $229.14 million, a P/E ratio of -1.70 and a beta of 2.42.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.08. During the same quarter last year, the company earned ($0.15) earnings per share. Equities research analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

A number of hedge funds have recently bought and sold shares of OMER. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Omeros by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 1,110 shares during the period. Truvestments Capital LLC increased its holdings in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares during the last quarter. Deutsche Bank AG boosted its stake in Omeros by 4.9% in the first quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company’s stock valued at $345,000 after acquiring an additional 1,973 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in Omeros by 2.0% in the fourth quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company’s stock valued at $1,190,000 after acquiring an additional 2,317 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.